Special Issue

‘Non-traditional’ Antimicrobial Approaches to Combat Antimicrobial Resistance

Message from the Guest Editor

For years, the threat of antimicrobial resistance (AMR) has been looming over the global population, threatening the security of public health. With the advent of numerous multidrug-resistant organisms (MDROs) that have evolved to resist a multiplicity of conventionally used antimicrobials, it is now vital that we develop strategies to combat infectious diseases. The purpose of this Special Issue, entitled ‘“Non-traditional” antimicrobial approaches to combat antimicrobial resistance’, is to compile a collection of manuscripts that are involved with developing novel and highly effective therapeutics that aim to adjust the clinical paradigm and quell the negative effects of AMR. Research into novel light-based antimicrobial approaches, phage therapeutics, peptide nucleic acids, antimicrobial peptides, probiotics, plant-based antimicrobials, combination therapies, boosting conventional antimicrobials (such as with the use of adjuvants), and all other non-traditional methods focused on treating infectious diseases are welcome.

Guest Editor

Dr. Leon G. Leanse

Europa Point Campus, University of Gibraltar, Gibraltar, MI, USA

Deadline for manuscript submissions

closed (15 July 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/175463

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI